Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies.
Camptothecin (CPT) inhibits the growth of a wide variety of experimental tumors. As a part of our exploration of this drug for use as a cancer chemotherapeutic agent, we studied the effect of route of administration on the absorption, distribution and tumor uptake of [3H]-CPT. The rate of disappearance of [3H]-CPT-derived radioactivity from blood during the first 48 h was highest following oral than following intravenous (i.v.) administration. Thereafter blood levels were low irrespective of route of administration. Considerable [3H]-CPT-derived radioactivity was detected in urine and feces up to 48 h after dosing. Distribution studies were conducted using quantitative whole-body autoradiography (WBA). These studies revealed that independent of the route of administration, [3H]-CPT was rapidly excreted in the bile (gallbladder) followed by elimination into the small and large intestinal tract. Levels of CPT-derived radioactivity in the kidneys were minimal and mostly localized in the renal pelvis. Hepatic concentrations of CPT were low and were almost equal to those of the tumor. The lungs of animals treated i.v. showed higher uptake of radioactivity than those treated intramuscularly or orally. Tumor/blood ratios were slightly higher following oral administration than following administration by other routes. This study indicates that CPT is primarily eliminated via the bile. The gastrointestinal tract is the major site of accumulation and excretion of CPT.
Ahmed
A E
AE
Department of Pathology and Cancer Center, The University of Texas Medical Branch, Galveston 77555-0609, USA.
Jacob
S
S
Giovanella
B C
BC
Kozielski
A J
AJ
Stehlin
J S
JS
Liehr
J G
JG
D000284:Administration, Oral; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D001345:Autoradiography; D002166:Camptothecin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D003110:Colonic Neoplasms / Q000378:metabolism*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D051379:Mice; D008819:Mice, Nude; D014018:Tissue Distribution
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin